Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays.

Authors: Cheung, HC  Baggerly, KA  Tsavachidis, S  Bachinski, LL  Neubauer, VL  Nixon, TJ  Aldape, KD  Cote, GJ  Krahe, R 
Citation: Cheung HC, etal., BMC Genomics. 2008 May 12;9:216. doi: 10.1186/1471-2164-9-216.
Pubmed: (View Article at PubMed) PMID:18474104
DOI: Full-text: DOI:10.1186/1471-2164-9-216

BACKGROUND: Tumor-predominant splice isoforms were identified during comparative in silico sequence analysis of EST clones, suggesting that global aberrant alternative pre-mRNA splicing may be an epigenetic phenomenon in cancer. We used an exon expression array to perform an objective, genome-wide survey of glioma-specific splicing in 24 GBM and 12 nontumor brain samples. Validation studies were performed using RT-PCR on glioma cell lines, patient tumor and nontumor brain samples. RESULTS: In total, we confirmed 14 genes with glioma-specific splicing; seven were novel events identified by the exon expression array (A2BP1, BCAS1, CACNA1G, CLTA, KCNC2, SNCB, and TPD52L2). Our data indicate that large changes (> 5-fold) in alternative splicing are infrequent in gliomagenesis (< 3% of interrogated RefSeq entries). The lack of splicing changes may derive from the small number of splicing factors observed to be aberrantly expressed. CONCLUSION: While we observed some tumor-specific alternative splicing, the number of genes showing exclusive tumor-specific isoforms was on the order of tens, rather than the hundreds suggested previously by in silico mining. Given the important role of alternative splicing in neural differentiation, there may be selective pressure to maintain a majority of splicing events in order to retain glial-like characteristics of the tumor cells.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 9686067
Created: 2015-01-29
Species: All species
Last Modified: 2015-01-29
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.